所有图片(1)
别名:
AL 4862, （5R）-5-乙基氨基-3-（3-甲氧基丙基）-2,2-二氧代-2?6,9-二硫杂-3-氮杂双环[4.3.0]壬-7,10-二烯-8-磺酰胺, （R）-4-（乙基氨基）-3,4-二氢-2-（3-甲氧基丙基）-2H-噻吩并[3,2-e] -1,2-噻嗪-6-磺酰胺1,1-二氧化物
经验公式（希尔记法）:
C12H21N3O5S3
推荐产品
质量水平
检测方案
≥98% (HPLC)
形式
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: ≥10 mg/mL
储存温度
−20°C
SMILES字符串
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI
1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChI key
HCRKCZRJWPKOAR-JTQLQIEISA-N
基因信息
human ... CA2(760)
正在寻找类似产品? 访问 产品对比指南
一般描述
布林佐胺是一种小分子量的化合物，能结合黑色素。该药可用于眼部治疗。
应用
在黑色素结合测定中，布林佐胺已被用作黑色素结合化合物或药物。它也被用作碳酸酐酶抑制剂（CAI）。
生化/生理作用
布林佐胺是一种用于降低眼压的碳酸酐酶 II 抑制剂。
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
John H K Liu et al.
Ophthalmology, 118(10), 1995-2000 (2011-06-17)
A core assumption for the 1-eye therapeutic trial of ocular hypotensive medications is the symmetrical reduction of intraocular pressure (IOP) in paired eyes. This assumption was evaluated for 24-hour IOP reduction in patients who underwent monotherapy or adjunctive therapy. Database
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality
Ingrida Januleviciene
Current medical research and opinion, 26(11), 2575-2578 (2010-09-28)
To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1%/timolol 0.5%. Medline was searched for brinzolamide/timolol fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide/timolol literature was reviewed. Compared with another
Ivan Goldberg et al.
Journal of glaucoma, 21(1), 55-59 (2010-11-05)
To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(5), 685-690 (2011-03-10)
To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. 6-month, multicenter, open-label, prospective, switch study
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门